COVID-19 Oral Antivirals for Pharmacist Only Supply
On July 14th 2022, the Associate Health Minister announced that Nirmatrelvir with Ritonavir (Paxlovid™) and Molnupiravir (Lagevrio®) were reclassified from prescription-only medicine to pharmacist-only (restricted) medicine.
The aim of this change is to increase timely access by allowing pharmacists to provide these oral antiviral medicines without a prescription to people who have COVID-19 and who meet the eligibility criteria set by PHARMAC.
PSNZ has developed a training programme for pharmacists (and other health professionals). The programme will give you the tools needed to appropriately supply these medicines to our most vulnerable patients.